VVOS Stock Analysis: Buy, Sell, or Hold?
VVOS - Vivos Therapeutics, Inc. Common Stock
$0.30
0.02 (6.41%)
▲
5d:
-13.49%
30d:
-23.96%
90d:
-49.21%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When VVOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VVOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VVOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VVOS is currently trading at $0.30, which is considered oversold relative to its 30-day fair value range of $0.31 to $0.42.
Technical Outlook: Technically, VVOS is in a strong downtrend. Immediate support is located at $0.26, while resistance sits at $0.36. The stock is showing strong short-term momentum, up 6.4% recently.
Market Sentiment: VVOS scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $2.12 (+612.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VVOS is in a strong downtrend. Immediate support is located at $0.26, while resistance sits at $0.36. The stock is showing strong short-term momentum, up 6.4% recently.
Market Sentiment: VVOS scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $2.12 (+612.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.31 -
$0.42
Company Quality Score
56/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: Strong upward momentum (+6.4%)
- BULLISH: Trading 612.7% below Wall St target ($2.12)
- CAUTION: Bottoming setup, but lagging the sector by 24% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-13.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.31 -
$0.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.26
Resistance Level
$0.36
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.36
Wall Street Target
$2.12
(+612.7%)
Revenue Growth (YoY)
34.9%
Profit Margin
-121.8%
Share & Embed Analysis
Last updated: August 22, 2026 11:49 AM ET
Data refreshes hourly during market hours. Next update: 12:49 PM
Data refreshes hourly during market hours. Next update: 12:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VVOS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Michael C Skaff
BUY
1353625 shares
2026-03-31
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 37 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
